

How to Cite:

Al Shammari, Y. H., Al Shammari, H. A., Barak, T. M. B., Alharbi, B. S., Alshammari, S. T., Alnais, S. A., Aljohani, S. A., Alorf, A. A., Alnawmasi, M. A., Alshammari, M. A., Alharbi, M. F., Al Enazi, A. G., & Alamri, A. M. M. (2019). Smart pills: the future of adherence monitoring. *International Journal of Health Sciences*, 3(S1), 1–15. <https://doi.org/10.53730/ijhs.v3nS1.14916>

Smart pills: the future of adherence monitoring

Yosef Houmid Al Shammari

KSA, National Guard Health Affairs
Email: zx5zx6@hotmail.com

Homoud Awade Al Shammari

KSA, National Guard Health Affairs
Email: Abomlk022@gmail.com

Talal Muhammad bin Barak

KSA, National Guard Health Affairs
Email: gdmol2014@gmail.com

Bandar Said Alharbi

KSA, National Guard Health Affairs
Email: aa4605a@gmail.com

Saud Tawfiq Alshammari

KSA, National Guard Health Affairs
Email: Tobksa79@gmail.com

Saleh Abdullah Alnais

KSA, National Guard Health Affairs
Email: Salehalnais22@gmail.com

Saeed Awad Aljohani

KSA, National Guard Health Affairs
Email: 4uvideoclip@gmail.com

Abdulrahman Abdullah Alorf

KSA, National Guard Health Affairs
Email: abdulrahmanab7557@gmail.com

Meshari Abdulmajeed Alnawmasi

KSA, National Guard Health Affairs
Email: Alnomasime@gmail.com

Mohammed Awad Alshammari

KSA, National Guard Health Affairs
Email: alshammarimo15@nghi.med.sa

Majed Farhan Alharbi

KSA, National Guard Health Affairs

Email: Alharbima2@ngha.med.sa**Abdulrahman Gobile Al Enazi**

KSA, National Guard Health Affairs

Email: Alenazia13@ngha.med.sa**Abdulelah Mohammed Mubashir Alamri**

KSA, National Guard Health Affairs

Email: Deloo.hellcat@gmail.com

Abstract--Background: The precise assessment and monitoring of patient medication adherence is a worldwide concern due to the lack of universally accepted methodologies for accurately measuring adherence. There has been recent focus on using technology to monitor medication adherence, since they allow for continuous surveillance of an individual's behavior in taking their prescription. Nevertheless, the existing technologies for monitoring medication adherence range in terms of their technological characteristics and techniques of data collection, resulting in variations in their individual benefits and constraints. There is a dearth of suitable criteria to guide the evaluation of medication adherence monitoring devices for optimum uptake and utilization. Aim of Work: The objective of this research is to conduct a narrative evaluation of existing technologies for monitoring medication adherence and to suggest a set of criteria for assessing these technologies, which will aid in the development and implementation of such technologies. Methods: Using the terms medication adherence, measuring technology, and monitoring technology, a literature search was carried out on PubMed, Scopus, CINAHL, and ProQuest Technology Collection (2010-present). The selection concentrated on research concerning the technology used to monitor medication adherence, as well as its development and use. The technical characteristics, methods of data collection, and possible benefits and drawbacks of the identified technology applications were extracted. Additional techniques for using data for adherence monitoring were also found. Recurring aspects that were often seen were combined to provide prospective criteria for assessing technology. Results: The technical aspects of different technology types differed, but they all aimed to reliably monitor medication adherence and encourage adoption in patients' everyday lives. This was achieved via their unobtrusiveness and comfort of use. The majority of technologies were capable of offering real-time monitoring of medication-taking behaviors, but, they depended on indirect indicators of medication adherence. There have been few reports of successful deployment of these technologies in clinical settings. A total of 28 criteria for evaluating technology were defined and grouped into five categories: development information, technical characteristics, adherence to data collection and management,

feasibility and implementation, and acceptability and usability. Conclusion: This study provides an overview of the technical characteristics, methods of data collection, and the pros and cons of medication adherence monitoring technology discussed in existing literature. It also presents the suggested criteria for evaluating medication adherence monitoring technologies. This set of evaluation criteria may serve as a valuable instrument to direct the advancement and choice of pertinent technologies, enabling the ideal adoption and efficient use of technology to enhance medication adherence results. Additional research is required to evaluate the criteria used to assess medication adherence monitoring technologies and develop a suitable framework for technology evaluation.

Keywords---Medication Adherence, Technology Evaluation, Remote Sensing Technology, Telemedicine, Smart Pills.

Introduction

Precisely assessing and tracking patient medication adherence is of utmost importance in both clinical practice and research contexts, although it remains a difficult undertaking worldwide. Multiple techniques are used to assess medication adherence, including patient self-reports, pill counts, pharmacy refill records, drug metabolites or biomarker tests, and directly observed treatment (DOT) [1]. Nevertheless, none of these approaches have been universally recognized as a standardized means of assessing medication adherence in various contexts [2]. In recent times, there has been a growing use of sensor technologies to monitor the medication adherence of patients. An example of this is the Medication Event Monitoring System (MEMS), which is capable of documenting each instance when the patient accesses the pill container by use of a sensor that is integrated into the top of the pill bottle [3,4]. These technologies provide a distinct opportunity to assess and track the extent to which patients adhere to their treatment regimen over a period of time. Some studies [3-9] have claimed that medication adherence monitoring technology is the most accurate method for measuring patient medication adherence. However, other researchers [10-15] have chosen to ignore this assumption. The absence of adequate technology evaluation criteria in the area of medication adherence monitoring has led to insufficient agreement on how to decide or pick the suitable technology for application.

The literature has provided descriptions of the benefits and drawbacks of the often used techniques for monitoring drug adherence. For instance, Directly Observed Therapy (DOT) enables the direct monitoring of patients' medication-taking behavior [16-18]. However, it is costly to maintain and imposes a restrictive time burden on both healthcare practitioners (HCPs) and patients' daily routines [1,12,18,19]. Patient self-reporting is a commonly used method to evaluate medication adherence. It allows patients to have control over reporting their own adherence. However, there is a danger that patients may either overestimate or underestimate their ability to stick to their prescription regimen [20-22]. Ongoing advancements are being made in the development and

enhancement of medication adherence monitoring devices, which come in different varieties and provide diverse functionalities [1]. Users may be unfamiliar with distinctive aspects of freshly emerging technology [23]. However, there is currently no comprehensive description or synthesis that accurately captures the distinct qualities and benefits of various drug adherence monitoring devices. There is an increasing need for technology evaluation criteria that may provide guidance in the development and selection of suitable technologies for monitoring medication adherence, with the goal of enhancing patient outcomes [24].

Stakeholders have different expectations when it comes to using health information technology for monitoring drug adherence. When choosing monitoring technology, clinicians prioritize a user-friendly interface and precise adherence monitoring [1]. From a technological standpoint, although maintaining high system accuracy and data integrity is important, developers must also take into account the viability of technical engineering aspects of the system, such as energy consumption and battery lifespan [25]. Advanced medication adherence monitoring systems provide the ability to obtain patient medication adherence information via several methods, rather than being restricted to just one approach. Furthermore, the use of these technologies might be complex due to the extensive medical and pharmacological aspects, as well as the multifaceted behaviors of patients when it comes to following their drug regimen [22]. An exhaustive compilation and evaluation of the existing applications of medication adherence monitoring technologies is crucial for gaining a comprehensive knowledge of their capabilities and effectiveness. This information is essential for making informed choices on their acceptance and use.

Aim of Work

The aim of this narrative review is to provide a concise summary of existing literature on the current uses of medication adherence monitoring technologies and to offer possible evaluation criteria that might assist in making choices on the development and use of such technologies.

Methods

The PubMed, Scopus, CINAHL, and ProQuest Technology Collection databases were selected for their extensive range of literature pertaining to health, healthcare, and technology. The search query consisted of the phrases "medication adherence" combined with "measurement technology" or "monitoring technology". The document contains a comprehensive compilation of search techniques used for each database.

Types and Characteristics of Technology

Out of the 98 papers that were evaluated, 81% of them documented the use of medication adherence monitoring technologies. The technology types that were identified have been classified into eight major groups according to their technical designs and functions for monitoring adherence. These groups include electronic pillboxes or bags, electronic pill bottles, ingestible sensors, blister pack

technology, electronic medication management systems, patient self-report-based technology, video-based technology, and motion sensor technology.

Smart Pill Bottles

This technology comprises a conventional-sized pill bottle and an electronic cap equipped with a microchip. It captures a date and time stamp when the cap is removed during an opening event. The transmission of adherence data is contingent upon the specific version of the electronic pill bottle device. Certain outdated iterations of the MEMS (Microelectromechanical Systems) often need the manual retrieval of patient medication adherence data from the MEMS cap. This data is then transferred into the MEMS software using a compact reader device [8-10,27,28]. Advanced electronic pill bottle technologies like the GlowCap and AdhereTech devices have the capability to communicate patient medication adherence data wirelessly. This allows for real-time assessment and monitoring of patient medication adherence [1,15,18,29-31].

Electronic pill bottle technologies are often cited for their discreet and compact form [10,16,32,33], capacity to objectively monitor medication adherence [1,8,11,14,34,35], and high acceptability among patients [1,30,31]. Nevertheless, due to the limitation of the pill bottle design to accommodate just one kind of medicine at a time, these devices are not appropriate for patients who have complicated multidrug regimens [1,4,8,9,18,30,32]. Furthermore, the act of opening a pill bottle is often used as a way to determine if a patient is taking their medication as prescribed. However, certain patient behaviors such as not actually consuming the removed medications, taking out multiple doses at once, or simply opening the bottle out of curiosity without taking any medication can result in inaccurate assessments of medication adherence [1,2,4,5,9-11,14-16,27,28,30,33,36,37].

Electronic pill dispensers or containers

Electronic pill boxes or bags, like the electronic pill bottle technology, register a date-and-time stamp each time they are opened. However, in contrast to electronic pill bottles, these technologies often include the capability to store many varieties or potencies of medicine in different compartments inside the device. The dimensions and storage capacity fluctuate among the many kinds of electronic pill boxes or bags that are now available. The majority of the electronic pill boxes or bags that were found had the capability to communicate data on patient medication adherence in real time. This data may be sent by current cellular networks [1,9,26-28,38-43], wireless Bluetooth, or general packet radio service [1,27,44,45,46]. One device required the manual downloading of patient adherence data during clinic visits [47]. The ability of these devices to hold several prescriptions makes them more suitable for complicated multidrug regimens. However, this benefit is contingent on the device, since they may vary significantly in size and pill storage capacity.

It was apparent when comparing the Wisepill device's storage capacity of 60 small-sized tablets with MedTracker's storage capacity of a week's worth of medicine [1,27,39,41,46,44]. Nevertheless, devices that are larger in size are

frequently characterized as conspicuous and pose greater threats to patient confidentiality, thereby restricting the device's suitability for patient populations, especially for individuals who prefer not to reveal their health condition (such as being HIV positive) to others. In addition, these devices are unable to directly verify the consumption of medications, which raises concerns about the accuracy of monitoring medication adherence. This is because certain patient behaviors, such as taking medication out of the container and curiosity-driven events, can affect the estimation of medication adherence rates. These concerns have been highlighted in various studies [1,10,15,16,26,27,30,38-40,44,48-50].

Blister Pack Technologies

Only 3 blister pack technology implementations were found without an attachable adhesive label that featured a microchip and conductive wire layout [4,36,51]. The act of extracting medicine from the blister pack caused a disruption in the label circuit, which was then detected and logged by the microchip along with a timestamp. Information on patient medication adherence is broadcast wirelessly to central servers and is often available to healthcare professionals (HCPs), enabling real-time monitoring of adherence [1,6,51-55]. The design of blister packs ensures that each dosage of medicine is stored in separate compartments. This allows for each removed dose to be recorded as a distinct event, which prevents patients from taking several doses at once or removing the packaging out of curiosity [56]. Currently, it has been discovered that removing a dose from these devices can sometimes and unintentionally damage the conductive tracks of the neighboring doses. This results in multiple removal events being registered, which reduces the accuracy of monitoring using these technologies [56,57]. Additionally, this approach of monitoring medication adherence is a surrogate measure and cannot definitively verify that patients have taken their medicine, which further decreases the precision of estimations about patient medication adherence [1,4,52,55].

Implantable Sensors

Ingestible sensors, often referred to as digital pills or digital ingestion monitoring, are composed of a technical system including microsensors, an adhesive external monitor worn on the belly, and a mobile application. The microingestible sensors are enclosed along with medicine and swallowed into the body, where the gastric secretions in the stomach breakdown the capsule that contains both the drug and the sensor. The sensor is activated when it comes into touch with stomach fluid, and it then sends a distinct signal to the external monitor. The identified ingestion event is sent to a mobile application that uploads the event's date and time stamp, along with other recorded physiological measurements (such as heartbeat), to a central server. These technological solutions have the benefit of directly seeing medicine consumption [3,13,15,16,30,37,58-65], as well as monitoring adherence in real-time [1,3,9,12,30,37,49,58,61-66]. By precisely recognizing specific instances of medicine consumption, these technologies may detect several instances of consumption simultaneously, thereby enhancing the precision of evaluating patient adherence rates to medication [60,61,65]. Furthermore, experimental observations have shown that ingestible sensors have a high accuracy in detecting ingesting events, with rates ranging from 95% to

99.1% [3,58,65]. Nevertheless, due to the direct consumption of technological sensors, there are significant issues about patient privacy and autonomy, primarily since these devices are intrusive in nature [9,13,20]. The significant drawbacks of these technologies include patient complaints of skin irritation produced by the external monitor and the likelihood of sensor retention inside the body [1,12,15,40,59,60, 61,63,64]. These limitations also pose potential concerns to patient health and safety.

Electronic Medication Management Systems

The Electronic Medication Management System (EMMS) encompasses a range of devices that differ in functionality, but share common features aimed at assisting patients in managing their medication and documenting their adherence patterns. Three innovative EMMS devices with intriguing functional features are the radio frequency identification (RFID)-based medication adherence intelligence system, ReX (DosentRx Ltd), and the Medication Behavior Monitoring System (MBMS) [44,67,68,69]. The RFID-based medication adherence intelligence system (RMAIS) consists of an RFID reader, scale, microprocessor, liquid crystal display screen, and a motorized rotating platform [44,67]. The patient's pill bottles are equipped with an RFID tag that contains the drug's details, including the name of the medication and the correct dosage [67]. During a designated time for administering medicine, the RMAIS system produces auditory reminders for taking medication and spins the appropriate pill container in front of the patient. The pill container is weighed by the scale located underneath the rotating platform, and the medicine information is shown using an RFID reader. Once the patient has taken out the medicine from the pill bottle, the scale assesses the weight of the bottle and utilizes the disparity in weight to calculate the quantity of doses that have been eliminated. When the system identifies instances of nonadherence, it notifies a healthcare professional (HCP) [44,67]. One benefit of this method is that it offers assistance to patients who have to manage complicated multidrug regimens by removing the requirement for patient decision-making on which medicine to take, the dosage, and the timing [67]. However, the accuracy of this approach is restricted since it serves as a proxy monitor of medication adherence and cannot verify the actual consumption of medicine [44].

ReX is a newly created device consisting of a medicine dispensing unit that may be used several times, a disposable cassette, a mobile application, and a cloud system called Dose-E Analytics [68]. The medicine of the patient is kept inside the device and can only be dispensed at the proper time, in the precise dosage, and directly into the patient's oral cavity. The mobile application uploads data on patient medication adherence from the drug dispensing unit to the Dose-E Analytics cloud system. This system can be accessed by healthcare professionals, enabling them to monitor medication adherence in real-time. An essential benefit of the device is its dispenser mechanism, which effectively prevents patients from taking excessive amounts of medicine and ensures that medication is administered at the precise time intervals [68]. Although the gadget can track the drug until it reaches the patient's lips, it is unable to verify if the medication has really been consumed, which limits the accuracy of its estimations about medication adherence.

MBMS devices use cutting-edge technology such as the Internet of Things, deep learning, and artificial intelligence. The MBMS stands out due to its integration of three distinct kinds of medication adherence monitoring technologies: electronic pillboxes, motion sensor technology, and video-based monitoring technology. The gadget employs a predetermined alert to encourage patients to adhere to their prescription regimen. When the patient gets close to the device, motion sensors installed around the patient's house detect the movement and send a signal to the MBMS device to start capturing a video of the patient's behavior with their medicine. After detecting the patient's action of lifting their arm to drink water, the gadget triggers the release of the correct medicine and amount from the inside pillbox onto a platform equipped with a scale. The Medication Adherence Behavioral Monitoring System (MBMS) assesses the patient's medication intake by analyzing the convergence of the scale to zero [67]. Healthcare professionals (HCPs) get weekly updates on adherence from the Medication-Based Monitoring System (MBMS). Roh et al [69] discovered that the use of an MBMS device resulted in improved medication adherence compared to those who did not utilize the device. Nevertheless, like RMAIS and ReX, the system's failure to identify real medicine use hinders its capacity to accurately monitor patient adherence to medication.

Collection and Use of Medication Adherence Data

Current medication monitoring systems vary not just in their technological aspects, but also in how they acquire data and utilize that data to evaluate patients' adherence to medicine. The capacity of the majority of medication adherence monitoring technologies to provide immediate observations of patient medication adherence behaviors is advantageous to healthcare professionals (HCPs) and researchers in order to avoid nonadherence and enable suitable treatments [1,15,36,37,70]. However, the majority of these technologies depend on indirect indicators of medicine adherence, such as occurrences of device opening. This, in turn, restricts the accuracy of the data they provide [2,9,11,14,16,27,30,33,37,41,48-50]. Moreover, there is a scarcity of reports on the effective incorporation of these technologies in clinical settings or the assimilation of patient medication adherence monitoring data into clinical practice.

An important obstacle is the lack of compatibility between these monitoring technology systems and existing clinical information systems and workflow. In order to enhance patient care, it is necessary to make it easier for clinical systems to include medication adherence monitoring technology. This may be achieved by ensuring that the technique used to gather adherence data is practical for the intended patients and that the collected data can be seamlessly incorporated into standard electronic health record systems. The study provides insights into the techniques of capturing medication adherence data and its use, which may assist healthcare professionals and researchers in choosing the most suitable technology for monitoring medication adherence. Developers should also take into account the consequences of capturing medication adherence data in clinical and research environments to provide enhanced user-friendliness for both patients and providers.

Criteria for Evaluating Technology

As far as we know, this is the first compilation of evaluation standards specifically targeting devices designed to track and measure patient compliance with medicine. The evaluation criteria consist of five main categories: development information, technical characteristics, adherence to data collection and management, feasibility and execution, and acceptability and usability. The stated criteria emphasize crucial characteristics of medication adherence monitoring systems that must be taken into account throughout the development and deployment of the technology. One crucial factor in using medication adherence monitoring technology is the cost. However, a frequent drawback of these technologies is their high price tags [1,2,5,7,9,12,18,27,38,54]. The suggested criteria prioritize the cost effectiveness of technology used to monitor medication adherence, specifically within the feasibility and implementation area. The expensive nature of devices limits their use in clinical and research environments, since other approaches such patient self-reports are much more cost-effective [1].

This compilation of assessment criteria was developed by examining the current literature. It also takes into account other challenges related to technology acceptance and technology design features, such as the risks to patient privacy and the impact of large device size on user adoption due to daily life inconveniences [25]. The suggested evaluation criteria, because to their complex character, may serve as a guide for enhancing these technologies in order to enhance medication adherence measures and monitoring.

Furthermore, our suggested evaluation criteria exhibited a structure similar to those of existing recognized frameworks for evaluating mobile health. An instance of an app evaluation framework, known as the pyramid model, was initially suggested by Henson et al [71] and later modified by the American Psychiatric Association as the App Evaluation Model. This model introduces a 5-level structure for evaluating apps, which includes categories such as access and background, privacy and security, clinical foundation, usability, and data integration towards therapeutic objectives [71,72]. Each area has distinct evaluation criteria. For instance, the usability category includes an assessment of ease of use [72]. Usability, privacy and security, and data integration are common technology evaluation criteria that may be used to evaluate both mobile health applications and medication adherence monitoring systems. Adherence monitoring technology has technological capabilities that help in storing and managing medication. This leads to specific criteria for evaluating it, such as the device's ability to store medication or the presence of date-and-time stamps that show when medication is taken. The criteria for assessing medication adherence monitoring technologies were developed by a thorough study of existing literature and synthesis of information. This process has established a strong evidence base, but it also highlights the need for further empirical testing and validation.

Constraints

This narrative review is subject to some constraints. Initially, our database selection and search methodologies may not have been enough comprehensive to

include all published material. In addition, we restricted our analysis to studies published in English, which may have resulted in the exclusion of medication adherence monitoring devices from non-English sources. The suggested criteria for assessing medication adherence monitoring technologies are based on the aspects highlighted in our literature research and synthesis. These criteria will undergo additional validation and evaluation. We did not examine in-depth information provided by individual manufacturers. Considering that this research only examined medication adherence technologies used to monitor pill form pharmaceuticals, it is important to note that the evaluation criteria and our results may not apply to other forms of medication. Significantly, a substantial number of the retrieved publications were pilot or feasibility studies. Therefore, our evaluation scope for the criteria may likewise be restricted to the first phases of technological development.

Conclusion

This narrative review provides an overview of the existing technical characteristics and techniques for collecting data. It discusses the benefits and drawbacks of monitoring technologies for medication adherence in pill form, and suggests a set of criteria for evaluating these technologies. The establishment of our evaluation standards is vital for the development and acceptance of these technologies. More specifically, more technical advancements are necessary to enhance the compatibility of medication adherence monitoring technology systems in clinical environments. The growing use of technology that monitor patient medication adherence has shown promise in enhancing patient medication adherence habits. While this technology approach to monitoring patient medication adherence may not be considered the most reliable way, its features have the potential to enhance patient medication adherence and contribute to better patient health outcomes in the long run.

References

1. Park LG, Howie-Esquivel J, Dracup K. Electronic measurement of medication adherence. *West J Nurs Res* 2015 Jan;37(1):28-49.
2. Walter T, Wang L, Chuk K, Ng P, Tannock IF, Krzyzanowska MK. Assessing adherence to oral chemotherapy using different measurement methods: lessons learned from capecitabine. *J Oncol Pharm Pract* 2014 Aug;20(4):249-256.
3. Profit D, Rohatagi S, Zhao C, Hatch A, Docherty JP, Peters-Strickland TS. Developing a digital medicine system in psychiatry: ingestion detection rate and latency period. *J Clin Psychiatry* 2016 Dec;77(9):1095-1100
4. De Bleser L, De Geest S, Vandenbroeck S, Vanhaecke J, Dobbels F. How accurate are electronic monitoring devices? A laboratory study testing two devices to measure medication adherence. *Sensors (Basel)* 2010;10(3):1652-1660
5. Nerini E, Bruno F, Citterio F, Schena FP. Nonadherence to immunosuppressive therapy in kidney transplant recipients: can technology help? *J Nephrol* 2016 Oct;29(5):627-636.

6. Arnet I, Walter PN, Hersberger KE. Polymedication Electronic Monitoring System (POEMS) - a new technology for measuring adherence. *Front Pharmacol* 2013;4:26
7. Miguel-Cruz A, Bohórquez AF, Parra PA. What does the literature say about using electronic pillboxes for older adults? A systematic literature review. *Disabil Rehabil Assist Technol* 2019 Nov;14(8):776-787.
8. Williams A, Low JK, Manias E, Dooley M, Crawford K. Trials and tribulations with electronic medication adherence monitoring in kidney transplantation. *Res Social Adm Pharm* 2016;12(5):794-800.
9. Levin JB, Sams J, Tatsuoka C, Cassidy KA, Sajatovic M. Use of automated medication adherence monitoring in bipolar disorder research: pitfalls, pragmatics, and possibilities. *Ther Adv Psychopharmacol* 2015 Apr;5(2):76-87
10. Davis A, Sarsembayeva L, Gulyaev V, Primbetova S, Terlikbayeva A, Mergenova G, et al. If you build it, will they use it? Preferences for antiretroviral therapy (art) adherence monitoring among people who inject drugs (PWID) in Kazakhstan. *AIDS Behav* 2019 Dec;23(12):3294-3305
11. Musinguzi N, Muganzi CD, Boum Y, Ronald A, Marzinke MA, Hendrix CW, Partners PrEP Ancillary Adherence Study Team. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. *AIDS* 2016 Apr 24;30(7):1121-1129.
12. Vallejos X, Wu C. Digital medicine: innovative drug-device combination as new measure of medication adherence. *J Pharm Technol* 2017 Aug 28;33(4):137-139
13. Wang R, Sitova Z, Jia X, He X, Abramson T, Gasti P, et al. Automatic identification of solid-phase medication intake using wireless wearable accelerometers. *Annu Int Conf IEEE Eng Med Biol Soc* 2014;2014:4168-4171.
14. Lyimo RA, van den Boogaard J, Msoka E, Hospers HJ, van der Ven A, Mushi D, et al. Measuring adherence to antiretroviral therapy in northern Tanzania: feasibility and acceptability of the Medication Event Monitoring System. *BMC Public Health* 2011 Feb 09;11:92
15. Chai PR, Castillo-Mancilla J, Buffkin E, Darling C, Rosen RK, Horvath KJ, et al. Utilizing an ingestible biosensor to assess real-time medication adherence. *J Med Toxicol* 2015 Dec;11(4):439-444.
16. DiStefano MJ, Schmidt H. mHealth for tuberculosis treatment adherence: a framework to guide ethical planning, implementation, and evaluation. *Glob Health Sci Pract* 2016 Jun 20;4(2):211-221
17. Manyazewal T, Woldeamanuel Y, Holland DP, Fekadu A, Blumberg HM, Marconi VC. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial. *Trials* 2020 May 05;21(1):383
18. Cross A, Gupta N, Liu B, Nair V, Kumar A, Kuttan R, et al. 99DOTS: a low-cost approach to monitoring and improving medication adherence. In: *Proceedings of the Tenth International Conference on Information and Communication Technologies and Development*. USA: Association for Computing Machinery; 2019 Presented at: ICTD '19: Tenth International

- Conference on Information and Communication Technologies and Development; January 4 - 7, 2019; Ahmedabad India p. 1-12.
19. Liu X, Blaschke T, Thomas B, De Geest S, Jiang S, Gao Y, et al. Usability of a medication event reminder monitor system (MERM) by providers and patients to improve adherence in the management of tuberculosis. *Int J Environ Res Public Health* 2017 Sep 25;14(10)
 20. Silva DS, Snyder J. The ethics of new technologies to track drug adherence. *CMAJ* 2018 Oct 09;190(40):1209-1210
 21. Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. *Transl Behav Med* 2015 Dec;5(4):470-482
 22. Kronish IM, Thorpe CT, Voils CI. Measuring the multiple domains of medication nonadherence: findings from a Delphi survey of adherence experts. *Transl Behav Med* 2021 Feb 11;11(1):104-113
 23. Faisal S, Ivo J, Patel T. A review of features and characteristics of smart medication adherence products. *Can Pharm J (Ott)* 2021;154(5):312-323
 24. Basu S, Garg S, Sharma N, Singh MM. Improving the assessment of medication adherence: challenges and considerations with a focus on low-resource settings. *Ci Ji Yi Xue Za Zhi* 2019;31(2):73-80
 25. Aldeer M, Javanmard M, Martin R. A review of medication adherence monitoring technologies. *Appl Syst Innovat* 2018 May 06;1(2):14.
 26. Nsengiyumva NP, Mappin-Kasirer B, Oxlade O, Bastos M, Trajman A, Falzon D, et al. Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support. *Eur Respir J* 2018 Nov;52(5)
 27. Campbell JI, Haberer JE. Cell phone-based and adherence device technologies for HIV care and treatment in resource-limited settings: recent advances. *Curr HIV/AIDS Rep* 2015;12(4):523-531.
 28. Haberer JE, Musunguzi N, Tsai AC, Boum Y, Bwana BM, Muzoora C, et al. Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring. *AIDS* 2017 Jan 02;31(1):169-171
 29. Mehta SJ, Asch DA, Troxel AB, Lim R, Lewey J, Wang W, et al. Comparison of pharmacy claims and electronic pill bottles for measurement of medication adherence among myocardial infarction patients. *Med Care* 2019 Feb;57(2):9-14.
 30. Garrison LE, Haberer JE. Technological methods to measure adherence to antiretroviral therapy and preexposure prophylaxis. *Curr Opin HIV AIDS* 2017 Sep;12(5):467-474.
 31. Zijp TR, Touw DJ, van Boven JF. User acceptability and technical robustness evaluation of a novel smart pill bottle prototype designed to support medication adherence. *Patient Prefer Adher* 2020;14:625-634
 32. Cho H, Flynn G, Saylor M, Gradilla M, Schnall R. Use of the FITT framework to understand patients' experiences using a real-time medication monitoring pill bottle linked to a mobile-based HIV self-management app: a qualitative study. *Int J Med Inform* 2019 Nov;131:103949
 33. Robiner WN, Flaherty N, Fossum TA, Nevins TE. Desirability and feasibility of wireless electronic monitoring of medications in clinical trials. *Transl Behav Med* 2015 Sep;5(3):285-293
 34. Van Diest AM, Ramsey R, Aylward B, Kroner JW, Sullivan SM, Nause K, et al. Adherence to biobehavioral recommendations in pediatric migraine as

- measured by electronic monitoring: the adherence in migraine (AIM) study. *Headache* 2016 Jul;56(7):1137-1146
35. Park S, Sentissi I, Gil SJ, Park W, Oh B, Son AR, et al. Medication event monitoring system for infectious tuberculosis treatment in morocco: a retrospective cohort study. *Int J Environ Res Public Health* 2019 Jan 31;16(3)
 36. De Bleser L, Vincke B, Dobbels F, Happ MB, Maes B, Vanhaecke J, et al. A new electronic monitoring device to measure medication adherence: usability of the Helping Hand™. *Sensors (Basel)* 2010;10(3):1535-1552
 37. Bell KM, Haberer JE. Actionable adherence monitoring: technological methods to monitor and support adherence to antiretroviral therapy. *Curr HIV/AIDS Rep* 2018 Oct;15(5):388-396
 38. Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, et al. Real-time adherence monitoring for HIV antiretroviral therapy. *AIDS Behav* 2010 Dec;14(6):1340-1346
 39. Musiimenta A, Atukunda EC, Tumuhimbise W, Pisarski EE, Tam M, Wyatt MA, et al. Acceptability and feasibility of real-time antiretroviral therapy adherence interventions in rural Uganda: mixed-method pilot randomized controlled trial. *JMIR Mhealth Uhealth* 2018 May 17;6(5):e122
 40. Sumari-de Boer M, Pima FM, Ngowi KM, Chelangwa GM, Mtesha BA, Minja LM, et al. Implementation and effectiveness of evriMED with short messages service (SMS) reminders and tailored feedback compared to standard care on adherence to treatment among tuberculosis patients in Kilimanjaro, Tanzania: proposal for a cluster randomized controlled trial. *Trials* 2019 Jul 12;20(1):426
 41. Ingerski LM, Loew M, Porter JS, Su Y, Zhang H, Hankins JS, et al. Use of wise device technology to measure adherence to hydroxyurea therapy in youth with sickle cell disease. *J Pediatr Hematol Oncol* 2021 Jan;43(1):19-25.
 42. Theng Y, Fernando O, Deshan C, Goh L, Hong J, Sen A, et al. CuePBox: an integrated physical and virtual pillbox for patient care. In: *Proceedings of the Extended Abstracts on Human Factors in Computing Systems*. 2013 Presented at: CHI '13: CHI Conference on Human Factors in Computing Systems; April 27 - May 2, 2013; Paris France p. 433-438.
 43. McGillicuddy JW, Weiland AK, Frenzel RM, Mueller M, Brunner-Jackson BM, Taber DJ, et al. Patient attitudes toward mobile phone-based health monitoring: questionnaire study among kidney transplant recipients. *J Med Internet Res* 2013;15(1):e6
 44. Aldeer M, Martin R. Medication adherence monitoring using modern technology. In: *Proceedings of the IEEE 8th Annual Ubiquitous Computing, Electronics and Mobile Communication Conference (UEMCON)*. 2017 Presented at: IEEE 8th Annual Ubiquitous Computing, Electronics and Mobile Communication Conference (UEMCON); Oct. 19-21, 2017; New York, NY, USA.
 45. Jung H, Seong SJ, Choi J, Cho J, Park S, Kim C, et al. The efficacy and stability of an information and communication technology-based centralized monitoring system of adherence to immunosuppressive medication in kidney transplant recipients: study protocol for a randomized controlled trial. *Trials* 2017 Oct 16;18(1):480

46. Bachman DM, Gifford AL, Keyi X, Li Z, Feng C, Brooks M, et al. Feasibility and acceptability of a real-time adherence device among HIV-positive IDU patients in China. *AIDS Res Treat* 2013;2013:957862
47. Wang N, Shewade HD, Thekkur P, Huang F, Yuan Y, Wang X, et al. Electronic medication monitor for people with tuberculosis: implementation experience from thirty counties in China. *PLoS One* 2020;15(4):e0232337
48. Drabarek D, Anh NT, Nhung NV, Hoa NB, Fox GJ, Bernays S. Implementation of medication event reminder monitors among patients diagnosed with drug susceptible tuberculosis in rural Viet Nam: a qualitative study. *PLoS One* 2019;14(7):e0219891
49. Subbaraman R, de Mondesert L, Musiimenta A, Pai M, Mayer KH, Thomas BE, et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. *BMJ Glob Health* 2018;3(5):e001018
50. Campbell JI, Musiimenta A, Burns B, Natukunda S, Musinguzi N, Haberer JE, et al. The importance of how research participants think they are perceived: results from an electronic monitoring study of antiretroviral therapy in Uganda. *AIDS Care* 2019 Jun;31(6):761-766
51. Siu HY, Mangin D, Howard M, Price D, Chan D. Developing and testing an electronic medication administration monitoring device for community dwelling seniors: a feasibility study. *Pilot Feasibility Stud* 2017;3:5
52. Hoshi K, Kawakami J, Aoki S, Hamada K, Sato K. Compliance monitoring system using screen printing technology based on conductive ink. *Technol Health Care* 2012;20(6):511-520.
53. Thakkar D, Piparva KG, Lakkad SG. A pilot project: 99DOTS information communication technology-based approach for tuberculosis treatment in Rajkot district. *Lung India* 2019;36(2):108-111
54. Schukat M, Rudroju B. DigiSpenser--a GSM-based drug management and compliance monitoring system. *Annu Int Conf IEEE Eng Med Biol Soc* 2011;2011:5311-5314.
55. Morak J, Schwarz M, Hayn D, Schreier G. Feasibility of mHealth and Near Field Communication technology based medication adherence monitoring. *Conf Proc IEEE Eng Med Biol Soc* 2012;2012:272-275
56. van Onzenoort HA, Neef C, Verberk WW, van Iperen HP, de Leeuw PW, van der Kuy PM. Determining the feasibility of objective adherence measurement with blister packaging smart technology. *Am J Health Syst Pharm* 2012 May 15;69(10):872-879.
57. Bruxvoort K, Festo C, Cairns M, Kalolella A, Mayaya F, Kachur SP, et al. Measuring patient adherence to malaria treatment: a comparison of results from self-report and a customised electronic monitoring device. *PLoS One* 2015;10(7):e0134275
58. Hafezi H, Robertson TL, Moon GD, Au-Yeung K, Zdeblick MJ, Savage GM. An ingestible sensor for measuring medication adherence. *IEEE Trans Biomed Eng* 2015 Jan;62(1):99-109.
59. Martani A, Geneviève LD, Poppe C, Casonato C, Wangmo T. Digital pills: a scoping review of the empirical literature and analysis of the ethical aspects. *BMC Med Ethics* 2020 Jan 08;21(1):3
60. Chai PR, Rosen RK, Boyer EW. Ingestible biosensors for real-time medical adherence monitoring: MyTMed. *Proc Annu Hawaii Int Conf Syst Sci* 2016 Jan;2016:3416-3423

61. Eisenberger U, Wüthrich RP, Bock A, Ambühl P, Steiger J, Intondi A, et al. Medication adherence assessment: high accuracy of the new Ingestible Sensor System in kidney transplants. *Transplantation* 2013 Aug 15;96(3):245-250
62. Kamal S, Rosen MI, Lazar C, Siqueiros L, Wang Y, Daar ES, et al. Perceptions of people living with HIV and HIV healthcare providers on real-time measuring and monitoring of antiretroviral adherence using ingestible sensors: a qualitative study. *AIDS Res Treat* 2020;2020:1098109
63. Browne SH, Umlauf A, Tucker AJ, Low J, Moser K, Garcia JG, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: a randomized controlled trial. *PLoS Med* 2019 Oct;16(10):e1002891
64. Flores GP, Peace B, Carnes TC, Baumgartner SL, Buffkin DE, Euliano NR, et al. Performance, reliability, usability, and safety of the ID-Cap system for ingestion event monitoring in healthy volunteers: a pilot study. *Innov Clin Neurosci* 2016;13(9-10):12-19
65. Chai PR, Carreiro S, Innes BJ, Rosen RK, O'Cleirigh C, Mayer KH, et al. Digital pills to measure opioid ingestion patterns in emergency department patients with acute fracture pain: a pilot study. *J Med Internet Res* 2017 Dec 13;19(1):e19
66. Rahman T. Should trackable pill technologies be used to facilitate adherence among patients without insight? *AMA J Ethics* 2019 Apr 01;21(4):332-336
67. McCall C, Maynes B, Zou C, Zhang N. RMAIS: RFID-based medication adherence intelligence system. In: *Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology*. 2010 Presented at: Annual International Conference of the IEEE Engineering in Medicine and Biology; Aug. 31 - Sept. 4, 2010; Buenos Aires, Argentina.
68. Shtrichman R, Conrad S, Schimo K, Shachar R, Machluf E, Mindal E, et al. Use of a digital medication management system for effective assessment and enhancement of patient adherence to therapy (ReX): feasibility study. *JMIR Hum Factors* 2018 Nov 26;5(4):e10128
69. Roh H, Shin S, Han J, Lim S. A deep learning-based medication behavior monitoring system. *Math Biosci Eng* 2021 Jan 28;18(2):1513-1528
70. Bilodeau G, Ammouri S. Monitoring of medication intake using a camera system. *J Med Syst* 2011 Jun;35(3):377-389.
71. Henson P, David G, Albright K, Torous J. Deriving a practical framework for the evaluation of health apps. *Lancet Digit Health* 2019 Jun;1(2):52-54
72. The app evaluation model. American Psychiatric Association. URL: <https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model> [accessed 2022-02-27].